Major Depressive Disorder

New Drug Application to be submitted for MDD in late 2022, with separate filing for PPD planned for early 2023. 

Sheldon Preskorn, MD, shares insights into drug mechanisms and delivery to better help patients with major depressive disorder.

Bringing science to the practice of psychiatry has been the personal goal of Sheldon H. Preskorn, MD—the Educator of the Year.

At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.

After a string of disappointing results, mirtazapine gets another look in a recent study.

How can clinicians distinguish between ordinary grief, depression, and prolonged grief disorder?

What are the risk factors for and prevalence overweight and obesity in patients with first-episode drug-naïve major depressive disorder?

Could the emerging field of epigenetics hold the key to catching postpartum depression before it happens?

If approved, SLS-002 would be only the second approved product for ASIB.

Is depression the same today as it was in the 17th century? Is it the same thing in Nigeria as it is in the United States? One of the foremost historians of psychiatry weighs in.

A growing body of scientific evidence suggests that mind-altering drugs, combined with psychotherapy, are effective treatments for some of the most stubborn psychiatric disorders.

Zuranolone showed statistically significant improvement in depressive symptoms in this latest study.

Medical aid in dying is available for psychiatric patients in European countries and Canada. Will the United States be next?

Will a new Canadian law overturn long-held ethical norms in psychiatry?

A daily serving of almonds improved depressive symptoms in diabetes, but will it work in non-diabetic depression?

Overwhelmed and encumbered agencies are increasingly unable to provide critical services for LGBTQ youth, leaving them powerless in impeding a downward spiral into homelessness and associated negative ramifications. There are 5 ways psychiatrists can help.

What treatments could handle both psychiatric emergencies and long-standings mental health conditions—in a hurry?

Can depression be passed on to future generations, and if it can, how can treatment help?

Sedation may not always be desirable, but it is difficult to avoid in psychiatry. Some of the most sedating medications are discussed.

The psychiatrist's armamentarium to treat depression holds promise with a growing arsenal of integrative and pharmacologic options.

The FDA cleared the way to use this deep transcranial magnetic stimulation system, which may be able to help treat depression in less than 5 minutes.

A recent study evaluated the everyday efficacy of this novel treatment for major depressive disorder.

Pain as a cultural construct considers conscious and unconscious biases, as well as methods for assessing and managing pain in all patient populations, including those with mental health challenges.

A study estimates the frequency and clinical correlates of GI symptoms during depressive episodes in a large, nationwide sample of patients with MDD in China.

A quick primer on nomenclature, issues to consider, and switching.

ECT has undoubtedly been foundational in the field of interventional psychiatry, yet controversy remains an underlying theme.

There is consistent evidence of benefits following state-of-the-art modified ECT.

No one has precise data about how many Americans receive ECT each year, let alone how many treatments each patients receives or how closely providers space treatments. This is a troubling dilemma, according to the authors.

The more tools we have in our treatment toolbox, the greater the likelihood that we will ultimately find a treatment (or combination of treatments) to improve a given patient’s functioning and quality of life.